Ascentage Pharma Group International is focusing on therapies in mainland China, with FDA clearance for lisaftoclax highlighting recent advancements.
6 reports, 3 independent
Updated Aug 20
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 6
- Developments
- 6
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ascentage Pharma Group International is focusing on therapies in mainland China, with FDA clearance for lisaftoclax highlighting recent advancements.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Ascentage Pharma Group International confirmed it has operational presence in Suzhou, China.Sub-event
- Company management of Ascentage Pharma Group International participated in a conference held in Suzhou.Sub-event
Ascentage focuses on therapies in mainland China, supported by FDA clearance for lisaftoclax.1 source
Ascentage Pharma Group International is focusing on therapies in mainland China, led by CEO Dajun Yang.1 source
Ascentage Pharma's novel cancer drug received approval from China's NMPA.1 source
China's NMPA approved Lisaftoclax.1 source
Keep exploring
The entities involved
-
mainland China
geopolitical area under the jurisdiction of the People's Republic of China, excluding Special Administrative Regions
- FDA
Related events
- Merck faces sales challenges in China while simultaneously seeking FDA approval for new drugs.
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
- FDA is adjusting drug review strategies, showing openness to less data, while China surpasses the U.S. in drug research.
- An experimental drug, sourced from China, is under FDA scrutiny after marketing claims of being 'the ultimate good' and subsequent warnings were issued.
Coverage
Newest first; wire copies grouped- Simply Wall St.Asian Growth Companies With High Insider Ownership To Watch As global markets navigate a complex landscape of inflation concerns and trade negotiations, Asian economies are experiencing notable shift
- GlobeNewswireAscentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA ROCKVILLE, Md.
- GlobeNewswireAscentage Pharma to Participate in Evercore China Biotech Summit ROCKVILLE, Md. and SUZHOU, China, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“
- Insider MonkeyAscentage Pharma Raises $192.3M Through Oversubscribed Offshore Share Placement Ascentage Pharma Group International (NASDAQ:AAPG) is one of the best performing mid cap stocks so far in 2025. On July
- Insider MonkeyAscentage Pharma’s Novel Cancer Drug Approved in China Ascentage Pharma Group International (NASDAQ:AAPG) is one of the best young stocks to buy and hold for 5 years. On July 10, Ascentage Pharma ann
- GlobeNewswireAscentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL ROCKVILLE, Md. and SUZHOU, China, July 10, 2025 (GLOBE NEWS